For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.
Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.
Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
A Guide to the Suddenly Crowded Republican Primary
Turned Away and Left at Sea
The Fight Over Phonics
The New Afghanistan, Through the Eyes of Three Women
Special Episode: A Crash Course in Dembow, a Misunderstood Pantry Staple and Simple Tips to Keep Calm and Carry On
America’s Big City Brain Drain
How the G.O.P. Picked Trans Kids as a Rallying Cry
Republicans Impeach One of Their Own
The Godfather of A.I. Has Some Regrets
Special Episode: An Interplanetary Jazz Legend, a Cosmic Vegetable and a Psychic Prodigy
The Ticking Clock of a U.S. Debt Default
The Headlines: May 26
Millions of Dollars, Thousands of Robocalls and 1 Legal Loophole
The Headlines: May 25
Ukraine Lost in Bakhmut. But It Has Much Bigger Plans.
The Headlines: May 24
The Supreme Court vs. Andy Warhol
The Headlines: May 23
Is Trump's Nomination Now Inevitable?
Introducing The Headlines: May 22
Create your
podcast in
minutes
It is Free
Up First
Marketplace
Today, Explained
Economist Podcasts
The Ezra Klein Show